Detalhe da pesquisa
1.
Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia.
Emerg Infect Dis
; 30(3): 568-571, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38407158
2.
Chronic Pulmonary Aspergillosis as a Considerable Complication in Post-Tuberculosis Lung Disease.
Semin Respir Crit Care Med
; 45(1): 102-113, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38196060
3.
Stereotactic body radiotherapy for recurrent hemoptysis due to chronic pulmonary aspergillosis: a case report and systematic review of the literature.
Strahlenther Onkol
; 199(2): 192-200, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36264357
4.
Tuberculosis incidence in foreign-born people residing in European countries in 2020.
Euro Surveill
; 28(42)2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855907
5.
Drug-resistant tuberculosis: advances in diagnosis and management.
Curr Opin Pulm Med
; 28(3): 211-217, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35220372
6.
Regimens for Drug-Resistant Tuberculosis.
N Engl J Med
; 388(2): 190, 2023 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36630637
7.
Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model.
Eur Respir J
; 58(3)2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33574078
8.
Defining Outcomes of Tuberculosis (Treatment): From the Past to the Future.
Respiration
; 100(9): 843-852, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34058739
9.
[Cough - an Interdisciplinary Condition: The Pneumologist's Perspective]. / Husten eine interdisziplinäre Krankheit.
Ther Umsch
; 78(4): 187-194, 2021.
Artigo
em Alemão
| MEDLINE | ID: mdl-33899515
10.
Two Pandemics, One Challenge-Leveraging Molecular Test Capacity of Tuberculosis Laboratories for Rapid COVID-19 Case-Finding.
Emerg Infect Dis
; 26(11): 2549-2554, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32956612
11.
Pulmonary Alveolar Microlithiasis Complicated by Tuberculosis.
N Engl J Med
; 384(10): e36, 2021 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33704940
12.
Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries.
Am J Respir Crit Care Med
; 198(3): 379-386, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29509468
13.
Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia.
Respiration
; 96(1): 52-65, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29635251
14.
Long-term multidrug- and rifampicin-resistant tuberculosis treatment outcome by new WHO definitions in Germany.
Eur Respir J
; 60(5)2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36423919
15.
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component.
Eur Respir J
; 59(5)2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35589114
16.
Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
Eur J Clin Pharmacol
; 72(8): 905-16, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27305904
17.
Personalized Medicine for Chronic Respiratory Infectious Diseases: Tuberculosis, Nontuberculous Mycobacterial Pulmonary Diseases, and Chronic Pulmonary Aspergillosis.
Respiration
; 92(4): 199-214, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27595540
18.
Multidrug-resistant tuberculosis in Europe, 2010-2011.
Emerg Infect Dis
; 21(3): 409-16, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25693485
19.
Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey.
Eur Respir J
; 45(4): 1081-8, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25395035
20.
'Tree-in-bud': thinking beyond infectious causes.
Respiration
; 89(2): 162-5, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25613822